Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology-Reference-Cited by-同舟云学术

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology

Published:2020-03-09 Issue:3 Volume:108 Page:494-505
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Janssen Julie M.¹,Dorlo Thomas P. C.¹,Steeghs Neeltje²,Beijnen Jos H.¹³,Hanff Lidwien M.⁴,Eijkelenburg Natasha K. A.⁴,Lugt Jasper⁴,Zwaan C. Michel⁴⁵,Huitema Alwin D. R.¹⁶

Affiliation:

1. Department of Pharmacy & Pharmacology Antoni van Leeuwenhoek/Netherlands Cancer Institute Amsterdam The Netherlands

2. Department of Clinical Pharmacology Division of Medical Oncology Antoni van Leeuwenhoek/Netherlands Cancer Institute Amsterdam The Netherlands

3. Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The Netherlands

4. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

5. Department of Pediatric Hematology and Oncology Erasmus Medical Center Rotterdam The Netherlands

6. Department of Clinical Pharmacy University Medical Center Utrecht Utrecht University Utrecht The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1808

Reference93 articles.

1. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective

2. From class waivers to precision medicine in paediatric oncology

3. New drugs for children and adolescents with cancer: the need for novel development pathways

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children;Cancer Chemotherapy and Pharmacology;2024-05-23

2. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?;Expert Review of Clinical Pharmacology;2024-02-12

3. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children;2023-12-08

4. Personalized Minimal Effective Concentration Therapy;Clinical Therapeutics;2023-12

5. Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib;Journal of Pharmaceutical and Biomedical Analysis;2023-05